Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists identify bladder cancer genes in cats and dogs
Veterinary pathologists from 17 countries took part in the research.

The research could pave the way for new treatments.

An international team of scientists, working on human muscle-invasive bladder cancer (MIBC), has found the shared genes which play a role in cats and dogs spontaneously developing urothelial carcinoma (UC).

It is hoped the research will help identify which genes to target when developing treatments for human patients with bladder cancer. Previous sequencing had discovered around 60 genes which could have an influence on the development of human MIBC.

The results could also inform the development of therapies for cats and dogs.

The study, which involved veterinary pathologists from 17 countries, gathered bladder cancer tissue samples from human, canine, and feline patients and matched it with ‘healthy tissue’ to identify which genes had mutated.

Of the 60 genes which are known to mutate in human MIBC, three were found in cats (TP53, FAT1, and NRAS) and two in dogs (ARID1A and KDM6A). The feline gene which mutated most often, TP53, is also the same which most frequently mutates in human MIBC.

Similar genetic events, such as mismatch repair deficiency and chromothripsis, were also discovered in all three species.

The study, which involved researchers from institutions including the Wellcome Sanger Institute and the University of Guelph in Canada, is the most extensive sequencing of canine bladder cancer to date and the first-ever sequencing of feline bladder cancer.

Dr Louise van der Weyden, a senior author of the study, said: “This was a triumphant effort, pulling together veterinary pathologists from all over the world. It really is remarkable to have such diversity in tissue samples, thus we can be confident about the generalisability of our research.

“Our findings show it is good to have multiple animal models for bladder cancer biology representing different driver genes to capture distinct patient populations. We hope our findings will inform research in this area to help not only humans who get bladder cancer – but animals too, as therapies can benefit both species.”

 

Image (C) Shutterstock

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.